Your browser doesn't support javascript.
loading
The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug.
Teng, Mingxing; Luskin, Marlise R; Cowan-Jacob, Sandra W; Ding, Qiang; Fabbro, Doriano; Gray, Nathanael S.
Afiliação
  • Teng M; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.
  • Luskin MR; Division of Hematologic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States.
  • Cowan-Jacob SW; Novartis Institutes for BioMedical Research, Novartis Campus, Basel CH-4056, Switzerland.
  • Ding Q; Allorion Therapeutics, Guangzhou, Guangdong 511300, China.
  • Fabbro D; Cellestia Biotech, Basel CH-4057, Switzerland.
  • Gray NS; Department of Chemical and Systems Biology, ChEM-H, Stanford Cancer Institute, School of Medicine, Stanford University, Stanford, California 94305, United States.
J Med Chem ; 65(11): 7581-7594, 2022 06 09.
Article em En | MEDLINE | ID: mdl-35609336
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Proteínas de Fusão bcr-abl Tipo de estudo: Diagnostic_studies / Screening_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Proteínas de Fusão bcr-abl Tipo de estudo: Diagnostic_studies / Screening_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article